Tempus AI, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TEM research report →
Range $50 – $100
Price Chart
About the company
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests.
- CEO
- Eric Lefkofsky
- IPO
- 2024
- Employees
- 3,800
- HQ
- Chicago, IL, US
AI snapshot
Six angles, distilled from the data.
TEM remains in a long-term uptrend but is still below its 200-day average, so the larger recovery is intact while the trend has not fully cleared. The stock is well off the 52-week high and still working through a volatile post-IPO range, with the setup favoring a base-building phase rather than a clean breakout.
Street sentiment stays constructive: consensus is Buy, with an average target of 77.83 versus a recent close near 63.62. Recent calls have leaned higher, including targets of 85, 89, 92, and 100, though a few firms remain Neutral, so the setup favors optimism with some dispersion.
The company has a strong recent beat streak, going 7-for-8 on EPS and topping estimates by 34.4% in the latest quarter. Next-year EPS is still expected to be slightly negative at -0.0396, so shareholders should watch whether revenue growth can keep translating into margin improvement.
Recent insider activity skews clearly bearish, with 15 sales and no purchases. The pattern is concentrated among top executives and directors, including the CEO, CFO, chief legal officer, and chief accounting officer, which makes the activity more meaningful than routine noise.
Growth is solid but profitability remains negative. Revenue rose 23.1% year over year, while gross margin held at 64.5% and net margin was -12.54%, showing strong unit economics but still-heavy operating losses.
TEM competes as a data-rich healthcare technology platform with diagnostics and AI tools, which gives it a differentiated growth profile versus traditional life sciences services peers. The valuation remains rich for the sector, with a negative P/E and a market cap that still prices in substantial future scaling.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.58B
- P/E
- -56.77
- Fwd P/E
- 98.82
- PEG
- 10.36
- P/S
- 7.00
- P/B
- 21.60
- EV/EBITDA
- -360.90
- Div Yield
- 0.00%
- Gross Margin
- 64.46%
- Op Margin
- -18.48%
- Net Margin
- -12.54%
- ROE
- -40.86%
- ROIC
- -13.35%
Latest fiscal year · YoY change
- Revenue
- $1.27B+83.4%
- Gross Profit
- $797.90M+109.4%
- Op Income
- $-252,872,000
- Net Income
- $-245,028,000+65.3%
- EPS
- $-1.41+69.3%
- OCF Growth
- -15.4%
- FCF Growth
- -16.2%
- 52W High
- $89.09
- 52W Low
- $40.77
- 50D MA
- $72.89
- 200D MA
- $57.57
- Beta
- 3.61
- RSI (14)
- 33
- Avg Volume
- 6.93M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tempus posted a strong Q3 with 23% revenue growth, its first meaningful EBITDA step-up, and raised full-year 2026 guidance on broad-based momentum in diagnostics and data.· November 2, 2026
- Total revenue was $412 million, up 23% year over year, with diagnostics at $304 million (+20%) and data and apps at $108 million (+33%).
- Adjusted EBITDA was $25.6 million, and management said the company “made the turn” on meaningful EBITDA generation this quarter.
- Tempus raised 2026 revenue guidance to $1.60 to $1.6 billion and reiterated about $65 million of adjusted EBITDA for 2026.
- Big strategic deals added visibility: BMS could contribute up to $138 million over 5 years, and the BMS/Pathos Alzheimer’s collaboration adds $55 million over 5 years.
- Management highlighted strong unit growth in oncology (32%) and hereditary cancer volume returning to low double digits, while data bookings and long-term contracts improved visibility into 2027+.
Q3 revenue was $412 million, up 23% year over year. Diagnostics revenue was $304 million, up 20% year over year; oncology revenue was $173 million and hereditary cancer testing revenue was $111 million. Data and apps revenue was $108 million, up 33% year over year, led by Insights growth of 29%. Adjusted EBITDA was $25.6 million, and the company ended the quarter with $854 million in cash and marketable securities. For 2026, Tempus raised revenue guidance to $1.60 to $1.6 billion and reiterated adjusted EBITDA of approximately $65 million.
Eric Lefkofsky framed Q3 as a broad-based inflection point, saying momentum carried from the first half into the third quarter and that the company is building a “data moat” through scale, AI capabilities, and provider connectivity. He emphasized strong operating trends in both core diagnostics and data, plus major strategic collaborations with BMS, Moderna, Merck, and Pathos. His tone was confident and expansive, repeatedly stressing that Tempus can sustain long-term 25%+ growth while still benefiting from future ASP tailwinds and MRD expansion.
Jim Rogers focused on margin leverage, saying Tempus has historically aimed to reinvest about two-thirds of incremental gross profit dollars back into the business and let roughly one-third drop to the bottom line. He said the company will absorb Personalis’ burn if the deal closes, but still expects EBITDA to improve, and cited the $854 million cash and marketable securities balance as support for growth plans. On oncology pricing, he said the updated XT pricing should add about $80 million of ASP uplift in 2027, with an even larger step-up possible when XF is FDA-approved.
Analysts pressed on hereditary testing headwinds, and management said the business is lapping unusually strong prior-year growth, with unit growth returning to low double digits and no material impact expected from Gamma on hereditary cancer rates. On MRD and Personalis, management said scaling is mostly about reimbursement and unit economics, with broader sales rollout likely to accelerate once the test turns positive gross profit dollar contribution, which they suspect could happen mid-2027. Questions on the data business centered on visibility and AI stickiness; management said long-term contracts, subscriptions, and customer use of Tempus’s in-environment GPU/model-building tools have made the business much “stickier” and improve visibility into 2027-2029.
The call showed broad revenue momentum, with both diagnostics and data growing at healthy double-digit rates and oncology unit volume rising 32%. Management also pointed to multiple new long-term strategic deals, rising oncology pricing, and expanding MRD adoption as potential growth accelerants. They sounded increasingly confident that the company can keep compounding at a 25%+ long-term rate while generating more EBITDA and cash.
Management acknowledged some hereditary testing growth normalization after an unusually strong prior year, and said reimbursement dynamics could create some macro headwind there. MRD is still constrained by reimbursement and current per-test economics, which means Tempus may not fully unlock the commercial opportunity until later in 2027. They also said Personalis is currently burning money, so the acquisition will temporarily add to reinvestment needs before it becomes accretive.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 70.9%
- Shares Outstanding
- 177.36M
- Float Shares
- 125.67M
of shares held by institutions
549 13F filers
Buy/sell ratio 0.04. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TEM, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 10.26M | ▲ 817.01K |
| Blackrock, Inc. | 9.62M | ▲ 1.33M |
| Ark Investment Management LLC | 9.36M | ▼ 665.09K |
| Baillie Gifford & Co | 6.91M | ▼ 1.28M |
| Softbank Group Corp. | 5.41M | 0 |
| Jpmorgan Chase & Co | 5.33M | ▲ 337.38K |
| Vanguard Capital Management LLC | 5.09M | ▲ 105.76K |
| Vanguard Portfolio Management LLC | 5.05M | ▲ 135.77K |
| Amova Asset Management Americas, Inc. | 3.40M | ▼ 688.15K |
| Sumitomo Mitsui Trust Group, Inc. | 3.40M | ▼ 688.15K |
| Franklin Templeton Inc | 3.14M | ▼ 212.77K |
| Gc Wealth Management Ria, LLC | 2.41M | ▼ 190 |
Held by 531 ETFs
Biggest fund positions in TEM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Polovin Andrew | sell | 2,103 |
| Nov 17, 26 | Polovin Andrew | sell | 4,020 |
| Nov 17, 26 | Polovin Andrew | sell | 581 |
| Nov 17, 26 | LEFKOFSKY ERIC P | sell | 5,367 |
| Nov 17, 26 | LEFKOFSKY ERIC P | sell | 10,225 |
| Nov 17, 26 | LEFKOFSKY ERIC P | sell | 1,482 |
| Nov 17, 26 | Rogers James William | sell | 2,225 |
| Nov 17, 26 | Rogers James William | sell | 4,240 |
| Nov 17, 26 | Rogers James William | sell | 614 |
| Nov 17, 26 | Fukushima Ryan | sell | 3,223 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TEM coverage
Recent articles, reports, and earnings notes.

Tempus AI (TEM): Growth Momentum vs. Profitability Risk
Tempus AI is scaling quickly in diagnostics and data licensing, with improving margins and a growing multimodal data asset. But losses, negative free cash flow, and leverage keep the stock in Hold territory.

Tempus AI, Inc. (TEM) climbs 12% on Q3 beat
Tempus AI, Inc. (TEM) climbs after posting a strong Q3 revenue beat, swinging to adjusted EPS profit, and lifting 2026 revenue guidance. The rally reflects improved operating leverage, stronger growth across its core businesses, and renewed investor confidence in the company’s outlook.

What to Watch as Pearl’s SPAC Merger Moves Toward Close
Pearl appears to be the dental AI company, and the deal context points to a possible public listing through K&F Growth Acquisition Corp. II (Nasdaq: KFII). But the SEC materials surfaced here do not verify a signed merger agreement, so investors should watch for the actual S-4/proxy, valuation, and financing terms before treating this as a live de-SPAC. The setup could be attractive if the company is real and the terms are clean, but the missing deal documents leave the core economics unconfirmed.
Want a deeper read on TEM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Tempus AI CEO Eric Lefkofsky on Cancer Data and the $1.5B Personalis Acquisition
youtube.com · Nov 20
Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027?
fool.com · Nov 19
Grail vs. Tempus AI: Which Healthcare Stock Is a Better Buy for 2027?
fool.com · Nov 19
Tempus AI: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 19
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
businesswire.com · Nov 17
Arizona Eagle Mining Corp. Announces Completion of High Resolution TEM Geophysical Survey at the Eagle Project and Provides Update on McCabe Mine Reopening Studies
newsfilecorp.com · Nov 12
Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting
businesswire.com · Nov 11
Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer
prnewswire.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice